Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis.
MS clinical trials: what can subgroup analyses teach us?
Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.
Status spongiosus of CNS and hepatic changes induced by cuprizone (biscyclohexanone oxalyldihydrazone).
The role of natural killer cells in multiple sclerosis and their therapeutic implications.
Masitinib mesylate application for conditional approval
Spectrophotometric Determination of Serum Copper with Biscyclohexanoneoxalyldihydrazone
Environmental factors in multiple sclerosis: Epstein-Barr virus, vitamin D, and cigarette smoking.
The force awakens: insights into the origin and formation of microglia.
Studies on the induction of hydrocephalus and spongy degeneration by cuprizone feeding and attempts to antidote the toxicity.
17beta-estradiol and progesterone prevent cuprizone provoked demyelination of corpus callosum in male mice.
Neuroprotection in a novel mouse model of multiple sclerosis.
Myelin Oligodendrocyte Glycoprotein-Associated Pediatric Central Nervous System Demyelination: Clinical Course, Neuroimaging Findings, and Response to Therapy.
US and EU regulatory authorities accept oral BG-12 marketing applications for review
Exposure levels of anti-LINGO-1 Li81 antibody in the central nervous system and dose-efficacy relationships in rat spinal cord remyelination models after systemic administration.
Characterisation of microglia during de- and remyelination: can they create a repair promoting environment?
Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination.
Interferon-β therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome.
The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk.
Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer's disease and other neurodegenerative diseases.
Assessment and Imaging of the Cerebrovascular Glycocalyx.
Cerebellar cortical demyelination in the murine cuprizone model.
Long-term efficacy and safety of transanal irrigation in multiple sclerosis.
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab.
Pages
« first
‹ previous
…
20
21
22
23
24
25
26
27
28
…
next ›
last »